Chemotherapy

Immunotherapy

Gastroenterology

Capecitabine

Oxaliplatin

Cancer

Internal medicine

Pathology

Placebo

Colorectal cancer

Surgery

Oncology

Alternative medicine

Nivolumab

Medicine

The Lancet Oncology

Nivolumab combined with oxaliplatin-based chemotherapy significantly improved progression-free survival, but not overall survival, in Asian patients with untreated, HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer, and could potentially be a new first-line treatment option for these patients.

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial